Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.
We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.
Thank you for your interest in ITM’s Precision Oncology Symposium 2021.
On behalf of ITM I would like to invite you to our virtual ancillary event ‘New Approaches for Targeted Radionuclide Therapy in Precision Oncology’ on Friday June 4, 2021 from 9:30-11:00 am EDT in parallel to the 2021 ASCO Annual Meeting.
Our symposium will be chaired by Dr. Richard Wahl, Mallinckrodt Institute of Radiology, St. Louis MO, US, who will introduce the faculty of renowned experts in the field, Dr. Jennifer Chan, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, US, Dr. Thorvardur Halfdanarson, Mayo Clinic, Rochester, MN, US and Dr. Mona Wahba, ITM, Munich, Germany.
Targeted Radionuclide Therapy is rapidly becoming a new treatment paradigm in oncology. After a brief introduction to the field, the symposium will focus on the application of Targeted Radionuclide Therapy in G1 and G2 neuroendocrine tumors (NETs) and in also the more aggressive G3 NETs. This will be followed by a look into the future, illustrated by ITM’s clinical development pipeline in precision oncology.
I look forward to welcoming you to join us in what promises to be an exciting overview of Targeted Radionuclide Therapy as an exemplar of precision oncology, with critical analysis of the latest science and clinical practice that is driving this treatment paradigm into the forefront of patient management.
We look forward to you joining us at the link below where you can also find all information, the program in advance and can register to participate.
Philip E Harris, PhD FRCP FRSB
Chief Medical Officer ITM
Chair: Richard L Wahl, MD
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, U.S.
Welcome & Introduction
Richard L Wahl, MD, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, U.S.
The potential for state-of-the-art Targeted Radionuclide Therapy & Diagnostics and future applications
Richard L Wahl, MD, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, U.S. (15 min)
The clinical management of NETs – a multi-disciplinary team approach
Jennifer A Chan, MD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, U.S. (15 min)
Leveraging the latest developments in somatostatin receptor-positive tumors to generate novel therapeutic opportunities
Thorvardur R Halfdanarson, MD, Mayo Clinic, Rochester, MN, U.S. (15 min)
ITM’s precision oncology pipeline
Mona M Wahba, MD, MSM, ITM, Munich, Germany (15 min)
Discussion & Closing Remarks